Denali Therapeutics Inc.

Ankita Srivastava

Adam P Silverman

Mihalis S Kariolis

Mark S Dennis

Ryan Jefferson Watts

Xiaocheng Chen

Joy Yu Zuchero

Robert C Wells

Cathal S Mahon

Rachel Prorok

Anastasia Henry

Gunasekaran Kannan

Katrina W Lexa

Bettina Van Lengerich

Kathryn M Monroe

Joshua I Park

Ray L Y Low

Julie Ullman

Sherie Duncan

Kathleen Lisaingo

Ju Shi

Riley Walsh

Gerald Maxwell Cherf

In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.

Anti-TREM2 antibodies and methods of use thereof

Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.

Methods of engineering transferrin receptor binding polypeptides

Provided herein are fusion proteins that comprise an enzyme replacement therapy enzyme and an Fc region, as well as methods of using such proteins to treat a lysosomal storage disorder. Methods for transporting agents across the blood-brain barrier are also provided herein.

Fusion proteins comprising enzyme replacement therapy enzymes

Engineered transferrin receptor binding polypeptides

Provided herein are progranulin variants and fusion proteins that comprise a progranulin variant and an Fc polypeptide. Methods of using such proteins to treat progranulin-associated disorders (e.g., a neurodegenerative disease, such as frontotemporal dementia (FTD)) are also provided herein.

Progranulin variants

Growing community of inventors

South San Francisco, CA, United States of America

Ankita Srivastava